BioSpace News Archive

NEW YORK and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with certain accredited investors, the majority of whom are existing investors of the Company, including Dr. Ray Prudo, Akari’s Chairman, to receive gross proce

SANTA BARBARA, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today that members of management are scheduled to present at the 9 th Annual SVB Leerink Global Healthcare Conference. Event: Date: Time: 9th Annual SVB Leerink Global Healthcare Conference Wednesday, February 26, 2020 11:30am ET An audio webcast of the Company’s presentation will be made available on the investor relatio

Feb. 20, 2020 22:54 UTC HAWTHORNE, N.Y.--( BUSINESS WIRE )-- Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling two (2) lots of Phenytoin Oral Suspension USP, 125 mg/5 mL both in 237 mL bottles, to the consumer level. Phenytoin Oral Suspension USP, 125 mg/5 mL is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and is packaged in amber plastic bottles with an inner seal and a white child proof closur

SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fo

Aerie Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2019, along with 2020 guidance and a general business update.

Alexion Pharmaceuticals announced that management will present at the SVB Leerink Global Healthcare Conference in New York, NY on Tuesday, February 25th, 2020 at 9:30 a.m. ET.

Cerus Corporation announced complete financial results for the fourth quarter and year ended December 31, 2019.

PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering. The proposed offering is

Conference call to discuss financial and operational results scheduled for Friday, February 21 at 8:30 a.m. U.S. Eastern Time

-- Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 -- -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C -- Conference Call Today at 4:30 p.m. (ET) --